Literature DB >> 19730132

P-selectin and P-selectin glycoprotein ligand 1 mediate rolling of activated CD8+ T cells in inflamed colonic venules.

Muhammad Asaduzzaman1, Andrada Mihaescu, Yusheng Wang, Tohru Sato, Henrik Thorlacius.   

Abstract

BACKGROUND: Activated T cells regulate inflammatory diseases in the intestinal tract; however, the adhesive mechanisms governing CD8 T-cell recruitment in the colon are not known.
METHODS: Herein, we used a graft-versus-host disease (GvHD) model to study CD8 T-cell rolling and adhesion in the large intestine by use of intravital fluorescence microscopy. Graft-versus-host disease was induced by transferring 50 x 10 allogeneic donor splenocytes from BDF1, B6, H-2b mice to recipient BDF1, H-2 mice. After 8 days, rhodamine-labeled CD8 T cells (4 x 10) from healthy and GvHD mice were injected into both healthy and GvHD recipient mice, and CD8 T-cell-endothelium interactions were studied in the colon.
RESULTS: Activated CD8 T cells from GvHD mice expressed higher levels of P-selectin ligand and decreased levels of L-selectin. Immunoneutralization of P-selectin and P-selectin glycoprotein ligand 1 reduced CD8 T-cell rolling and adhesion in inflamed colonic venules by more than 71%. Inhibition of E-selectin had no effect on GvHD-induced CD8 T-cell-endothelium interactions.
CONCLUSIONS: We conclude that P-selectin and P-selectin glycoprotein ligand 1 are dominating molecules in supporting adhesive interactions of CD8 T cells in inflamed colonic venules and may be useful targets to protect against pathological inflammation in the large bowel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19730132     DOI: 10.2310/JIM.0b013e3181b918fb

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  7 in total

Review 1.  PSGL-1: A New Player in the Immune Checkpoint Landscape.

Authors:  Roberto Tinoco; Dennis C Otero; Amy A Takahashi; Linda M Bradley
Journal:  Trends Immunol       Date:  2017-03-02       Impact factor: 16.687

2.  Type 1 diabetes predisposes to enhanced gingival leukocyte margination and macromolecule extravasation in vivo.

Authors:  C Sima; K Rhourida; T E Van Dyke; R Gyurko
Journal:  J Periodontal Res       Date:  2010-12       Impact factor: 4.419

3.  Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease.

Authors:  Laurent Burnier; François Saller; Linda Kadi; Anne C Brisset; Rocco Sugamele; Lucie Baudino; Françoise Bono; Jean-Marc Herbert; Peter Carmeliet; Marc Schapira; Shozo Izui; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

4.  Guideline for in vivo assessment of adherent and rolling leukocytes in human skin microvasculature via reflectance confocal videomicroscopy.

Authors:  Zijun Zhao; James Randall Patrinely; Inga Saknite; Michael Byrne; Eric R Tkaczyk
Journal:  Microcirculation       Date:  2021-09-17       Impact factor: 2.628

5.  Individual cell motion in healthy human skin microvasculature by reflectance confocal video microscopy.

Authors:  Inga Saknite; Zijun Zhao; J Randall Patrinely; Michael Byrne; Madan Jagasia; Eric R Tkaczyk
Journal:  Microcirculation       Date:  2020-05-14       Impact factor: 2.628

6.  A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease.

Authors:  Carina A Bäuerlein; Musga Qureischi; Zeinab Mokhtari; Paula Tabares; Christian Brede; Ana-Laura Jordán Garrote; Simone S Riedel; Martin Chopra; Simone Reu; Anja Mottok; Estibaliz Arellano-Viera; Carolin Graf; Miriam Kurzwart; Katharina Schmiedgen; Hermann Einsele; Matthias Wölfl; Paul-Gerhardt Schlegel; Andreas Beilhack
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

Review 7.  P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target.

Authors:  Silvere D Zaongo; Yanqiu Liu; Vijay Harypursat; Fangzhou Song; Huan Xia; Ping Ma; Yaokai Chen
Journal:  Front Immunol       Date:  2021-08-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.